Liquidia (NASDAQ:LQDA) Director Sells $2,248,047.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 62,550 shares of the business’s stock in a transaction on Friday, March 27th. The stock was sold at an average price of $35.94, for a total value of $2,248,047.00. Following the completion of the sale, the director directly owned 2,188,935 shares in the company, valued at $78,670,323.90. This trade represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $37.68 on Friday. The business has a fifty day moving average price of $37.38 and a 200-day moving average price of $32.21. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.01 and a quick ratio of 1.84. The company has a market capitalization of $3.32 billion, a PE ratio of -45.40 and a beta of 0.45. Liquidia Corporation has a 1-year low of $11.26 and a 1-year high of $46.67.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The firm’s revenue for the quarter was up 3072.4% compared to the same quarter last year. As a group, equities analysts expect that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LQDA. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Wells Fargo & Company lifted their target price on Liquidia from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Monday, March 23rd. Needham & Company LLC upped their price target on Liquidia from $52.00 to $54.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Lifesci Capital raised Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Finally, Oppenheimer boosted their target price on Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a research report on Thursday, March 12th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and a consensus target price of $43.44.

Institutional Trading of Liquidia

Hedge funds have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia during the 4th quarter valued at about $25,000. NewEdge Advisors LLC bought a new position in shares of Liquidia in the 2nd quarter worth approximately $25,000. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Liquidia in the third quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia in the third quarter worth approximately $34,000. Finally, Covestor Ltd grew its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after buying an additional 359 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).